Literature DB >> 12687909

Importance of hypoxia in the biology and treatment of brain tumors.

Jonathan P S Knisely1, Sara Rockwell.   

Abstract

The resistance of gliomas to treatment with radiation and antineoplastic drugs may result in part from the effects of the extensive, severe hypoxia that is present in these tumors. It is clear that brain tumors contain extensive regions in which the tumor cells are subjected to unphysiological levels of hypoxia. Hypoxic cells are resistant to radiation. Hypoxia and the perfusion deficits and metabolic changes that accompany hypoxia in vivo also produce resistance to many commonly used anticancer drugs. The resistance of cells that are hypoxic at the time of therapy may influence the efficacy of the treatment of these tumors with radiation, chemotherapy, and combined modality regimens. Moreover, it is becoming increasingly evident from laboratory studies that exposure of cells to adverse microenvironments produces transient changes in gene expression, induces mutations, and selects for cells with altered genotypes, thus driving the evolution of the cell population toward increasing malignancy and increasingly aggressive phenotypes. Hypoxia may therefore be involved in the evolution of cells in low-grade malignancies to the resistant, aggressive phenotype characteristic of glioblastomas. During the past 50 years, many attempts have been made to circumvent the therapeutic resistance induced by hypoxia, by improving tumor oxygenation, by using oxygen-mimetic radiosensitizers, by adjuvant therapy with drugs that are preferentially toxic to hypoxic cells, by using hyperthermia, or by devising radiation sources and regimens that are less affected by hypoxia. Past clinical trials have provided tantalizing suggestions that the outcome of therapy can be improved by many of these approaches, but none has yet produced a significant, reproducible improvement in the therapeutic ratio, which would be needed for any of these approaches to become the standard therapy for these diseases. Several ongoing clinical trials are addressing other, hopefully better regimens; it will be interesting to see the results of these studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12687909     DOI: 10.1016/s1052-5149(02)00032-1

Source DB:  PubMed          Journal:  Neuroimaging Clin N Am        ISSN: 1052-5149            Impact factor:   2.264


  17 in total

1.  Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma.

Authors:  F E Valles; C L Perez-Valles; S Regalado; R F Barajas; J L Rubenstein; S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2012-08-30       Impact factor: 3.825

2.  Truncated forms of BNIP3 act as dominant negatives inhibiting hypoxia-induced cell death.

Authors:  Nicolle Bristow; Teralee R Burton; Elizabeth S Henson; Coleen Ong-Justiniano; Michelle Brown; Spencer B Gibson
Journal:  Biochim Biophys Acta       Date:  2010-12-05

3.  Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines.

Authors:  Corinne E Griguer; Claudia R Oliva; G Yancey Gillespie
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

Review 4.  Hyperbaric oxygen therapy for malignancy: a review.

Authors:  Jurstine Daruwalla; Chris Christophi
Journal:  World J Surg       Date:  2006-12       Impact factor: 3.352

5.  Hypovascular Cellular Tumor in Primary Central Nervous System Lymphoma is Associated with Treatment Resistance: Tumor Habitat Analysis Using Physiologic MRI.

Authors:  S Y Jeong; J E Park; N Kim; H S Kim
Journal:  AJNR Am J Neuroradiol       Date:  2021-11-25       Impact factor: 3.825

6.  Construction of 6HRE-GFAP-Baxα system specific for glioma gene therapy.

Authors:  Yongji Tian; Guilin Li; Jun Gao; Renzhi Wang; Yanguo Kong; Zhenxing Zhang; Shifang Li; Shiqiang Tian; Wanchen Dou; Bo Zhang
Journal:  Front Med China       Date:  2007-02-01

Review 7.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.

Authors:  Randy L Jensen
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

Review 8.  Pharmacotherapy for adults with tumors of the central nervous system.

Authors:  Nina F Schor
Journal:  Pharmacol Ther       Date:  2008-11-27       Impact factor: 12.310

9.  Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome.

Authors:  Randy L Jensen; Michael L Mumert; David L Gillespie; Anita Y Kinney; Matthias C Schabel; Karen L Salzman
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

10.  KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology.

Authors:  Wei Wang; Lin Ao; Elizabeth R Rayburn; Hongxia Xu; Xiangrong Zhang; Xu Zhang; Subhasree Ashok Nag; Xuming Wu; Ming-Hai Wang; Hui Wang; Erwin G Van Meir; Ruiwen Zhang
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.